TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023

Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227.

Julie R Brahmer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.